GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSN) » Definitions » Cash Flow for Lease Financing

NeuroSense Therapeutics (NeuroSense Therapeutics) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics Cash Flow for Lease Financing?

NeuroSense Therapeutics's Cash Flow for Lease Financing for the three months ended in Dec. 2023 was $0.00 Mil. NeuroSense Therapeutics's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Sep. 2023 ), NeuroSense Therapeutics's Cash Flow for Lease Financing remained the same in Dec. 2023 ($0.00 Mil).


NeuroSense Therapeutics Cash Flow for Lease Financing Historical Data

The historical data trend for NeuroSense Therapeutics's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics Cash Flow for Lease Financing Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Lease Financing
- - - - -

NeuroSense Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NeuroSense Therapeutics Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeuroSense Therapeutics Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of NeuroSense Therapeutics's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11 HaMenofim Street, Building B, Herzliya, ISR, 4676670
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.